GeneDx Holdings Corp. (WGS)
| Market Cap | 1.16B -65.4% |
| Revenue (ttm) | 442.68M +34.1% |
| Net Income | -77.81M |
| EPS | -2.69 |
| Shares Out | 29.69M |
| PE Ratio | n/a |
| Forward PE | 94.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,154,137 |
| Open | 38.56 |
| Previous Close | 39.49 |
| Day's Range | 37.72 - 39.85 |
| 52-Week Range | 32.21 - 170.87 |
| Beta | 2.07 |
| Analysts | Strong Buy |
| Price Target | 86.67 (+122.57%) |
| Earnings Date | May 4, 2026 |
About WGS
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Financial Performance
In 2025, GeneDx Holdings's revenue was $427.54 million, an increase of 39.97% compared to the previous year's $305.45 million. Losses were -$21.02 million, -59.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price target is $86.67, which is an increase of 122.57% from the latest price.
News
Barrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities Fraud
PHILADELPHIA, May 12, 2026 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) The law firm of Barrack, Rodos & Bacine announces that it is investigating GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of shareholders...
GeneDx price target lowered to $85 from $153 at Craig-Hallum
Craig-Hallum analyst Bill Bonello lowered the firm’s price target on GeneDx (WGS) to $85 from $153 and keeps a Buy rating on the shares. The firm notes GeneDx missed Q1…
GeneDx Holdings Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of GeneDx Holdings Corp. (NASDAQ: WGS). The investigation focuses on GeneDx's ...
GeneDx price target lowered to $55 from $60 at TD Cowen
TD Cowen lowered the firm’s price target on GeneDx (WGS) to $55 from $60 and keeps a Buy rating on the shares. The firm updated its model following a braod-based…
GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks
BTIG lowered the firm’s price target on GeneDx (WGS) to $90 from $170 and keeps a Buy rating on the shares after its worth and expected Q1 results on guidance…
GeneDx price target lowered to $70 from $100 at Guggenheim
Guggenheim lowered the firm’s price target on GeneDx (WGS) to $70 from $100 and keeps a Buy rating on the shares. This “was a tough update, especially given that guidance…
GeneDx price target lowered to $75 from $155 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on GeneDx (WGS) to $75 from $155 and keeps an Overweight rating on the shares. The firm says the company…
GeneDx reports Q1 adjusted loss ($8.2M) vs. ($9.2M) last year
Reports Q1 revenue $102.3M, consensus $112.45M. The company said, “GeneDx (WGS) delivered 34% year-over-year volume growth in exome and genome testing in the first quarter – a clear signal that…
GeneDx Holdings Earnings Call Transcript: Q1 2026
Exome and genome test volumes grew 34% year-over-year in Q1, but revenue fell short due to lower average reimbursement rates and underperformance in non-core segments. Full-year guidance was reduced, with a focus on core diagnostics, cost control, and a return to adjusted profitability.
GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported first quarter financial results and business highlights, including 34% year-over-year volume growth in exome and genome testing.
GeneDx price target raised to $100 from $70 at Canaccord
Canaccord raised the firm’s price target on GeneDx (WGS) to $100 from $70 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results…
GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026.
Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio moves on Thursday, April 9, as shown in ARK’s daily fund disclosures. The ace hedge fund manager increased exposure to Gene...
GeneDx price target lowered to $100 from $170 at Guggenheim
Guggenheim analyst Subbu Nambi lowered the firm’s price target on GeneDx (WGS) to $100 from $170 and keeps a Buy rating on the shares. The firm adjusted models and forecasts…
GeneDx falls after Natera launches sequencing assay for rare diseases
Shares of GeneDx (WGS) are down $3.70 to $81.40 in premarket trading.
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing.
GeneDx Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
Significant expansion efforts are underway to move advanced genetic testing from niche expert use to broader pediatric, NICU, and prenatal markets, supported by dedicated sales teams and new customer experience tools. Education, payer coverage, and tailored engagement are key to driving adoption and utilization.
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--Announcing GeneDx's new genetic testing program with Zevra Therapeutics to support patients with suspected Niemann–Pick disease type C (NPC).
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be pr...
HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the upcoming TD Cowen and Barclays healthcare investor conferences.
GeneDx Holdings Earnings Call Transcript: Q4 2025
Q4 2025 saw 27% revenue growth and 71% gross margin, driven by exome/genome testing and market expansion. 2026 guidance projects $540M–$555M revenue and 33%–35% volume growth, with major investments in sales and R&D to capture new markets and sustain profitability.
INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.
GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.
TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World's Most Influential Leaders in Health
GAITHERSBURG, Md.--(BUSINESS WIRE)--TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List.